Trials / Completed
CompletedNCT05775601
18F-LY3950321-01 Biodistribution and Safety Study
A Phase 1, Open-label Study to Evaluate the Biodistribution and Safety of 18F-LY3950321 (18F-MNI-1256) in Healthy Subjects
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer targeting granzyme B. The overall goal of this protocol is to evaluate the safety, tolerability, and radiation dosimetry of 18F-LY3950321.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-LY3950321 | 3 millicuries (±1 mCi) |
| PROCEDURE | PET Scan | positron emission tomography (PET) scan |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
- First posted
- 2023-03-20
- Last updated
- 2023-04-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05775601. Inclusion in this directory is not an endorsement.